Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019 in Egyptian patients in military hospitals.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Oseltamivir

Criteria

Inclusion Criteria:

1. Adults from 18 to 60 years old who signed informed consent;

2. Laboratory confirmed SARS-CoV-2 infection by real-time RT-PCR.

3. Chest computed tomography (CT) imaging-confirmed lung damage, including multiple small plaques and stromal changes in the lungs, which are obvious in the outer lung, or multiple ground-glass shadows and infiltration shadows in both lungs, although these changes might not be present in mild patients.

4. Patients with history of fever (axillary temperature more than 37°С) or respiratory symptoms.

Exclusion Criteria:

1. Patients who are unsuitable or who cannot participate safely in the study, as judged by the principal investigator (PI).

2. Patients with serious liver disease (increase of liver transaminases enzymes).

3. Patients with severe renal impairment (denoted by increase serum urea & serum creatinine) or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.

4. Patients with severe anemia.

5. Women with a positive pregnancy test, ongoing pregnancy, or who are breastfeeding.

6. Patients with a history of allergy to medications or its metabolic components.

7. Patients who have not signed informed consent.

8. Patients participating in other clinical trials for COVID-19 within 30 days prior to screening.

9. Patients participating in other clinical research in the past three months.